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Non-specific cytotoxicity, mediated by Toxoplasma gondli
activated macrophages for the Fl and FlO B16 melanoma cells in vitro,
was examined in this study. In vitro cytotoxicity was assayed by
measuring the release of tritiated thymidine from pre-labeled tumor
cells during twenty four—hour and seventy-two hour assay periods.
Pre-labeled cells were incubated with peritoneal macrophages ob
tained from either uninfected CS7BL mice used as controls, or mice
latently infected with the C56 strain of Toxoplasma gondii.
There were significant differences observed in the total percent
of tritiated thymidine released spontaneously by the Fl and FlO B16
melanoma cells compared to Fl and FlO melanoma cells incubated with
macrophages obtained from either latently infected mice or unin
fected mice during both assay periods used. There was no signifi
cant difference in the percent tritiated thymidine released by the
Fl and F1O melanoma cells incubated with normal macrophages, compared
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to melanoma cells incubated with macrophages obtained from latently
infected mice.
When lysozyme activity was measured as an index of macrophage
activation, the extracts of macrophages derived from mice with latent
infection showed evidence of greater lysozyrne activity than the
extracts of macrophages obtained from uninfected mice.
There is evidence in this study to show that although infection
with Toxoplasma gondii did confer increased activation on macrophages,
this degree of activation was not sufficient enough to demonstrate
enhanced cytotoxic effect of the macrophages on the Fl and. FlO Bl6
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The role of the macrophage in tumor immunology has become
increasingly apparent in recent years. Mouse peritoneal macrophages
can be activated in vivo or in vitro for tumor cell killing, by
several seemingly unrelated mechanisms (Hibbs et al., 1971; Alexander
and Evans 1971; Keller and Jones, 1971; Cleveland et al., 1974; Kaplan
et al., 1974). Although the mechanisms by which activated macrophages
inhibit the growth of tumor cells in vivo or in vitro has not yet been
completely elucidated, it is known that such macrophages can be
specifically or non-specifically cytotoxic to tumor cells in vitro
(Hibbs et al., 1972; Evans and Alexander, 1971; Keller, 1973;
Churchill et al., 1975; Fidler, 1975; Sharmar and Piessens, 1978).
Macrophage cytotoxicity was said to be non-specific, because the
macrophages were activated by substances other, than the antigen
being suppressed. V
The role of Toxoplasma gondii in tumor suppression was first
demonstrated when latent infection with the parasite was found to
confer decreased incidence of tumor development in mice (Hibbs
et al., 1971). It was also found that peritoneal macrophages of
the latently infected mice were activated to kill or inhibit various
tumor cells in vitro (Hibbs et al., 1972).
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An in vivo. system developed by Fidler (1972.), which stimulates
metatasis, by intravenous injection of B16 melanoma cells can be used
to study the effect of various factors on the incidence of metastasis.
In Fidler’s study, decreased incidence of lung metastasis was noted in
mice immunized against the B16 melanoma tumor, compared to unstimulated
mice, when given intravenous injection of the tumor cells Norbury and
Fidler (1975) also described in vitro destruction of the B16 melanoma
tumor cells by immune syngeneic, allogeneic and xenogeneic mouse macro
phages. Fidler (1975) further reported that macrophages from unstimu
lated C57BL mice, when treated with supernatants from lymphocytes of
mice stimulated with the B16 melanoma tumor, were cytotoxic for the
melanoma cells in vitro. These observations thus showed that the
Bl6 melanoma tumor metastasis can be suppressed specifically, or non-
specifically in vivo, and that the tumor cells are susceptible to
specific or non-specific macrophage-mediated cytotoxicity.
In vivo suppression and in vitro macrophage-mediated cytotoxicity
induced by Toxoplasma gondii infection has been demonstrated for only
transplantable solid tumors. This study is part of a project designed
to determine whether •the induction of tumor suppression due to Toxo
plasma gondii infection extends to the suppression of the incidence of
Bl6 melanoma tumor cells metastasis in vivo, or their destruction in
vitro. This study was, therefore, undertaken to determine the in
vitro cytotoxic effect of Toxoplasma gondii—activated macrophages on
the Fl and FlO sublines of the Bl6 melanoma tumor. If macrophage
mediated cytotoxicity for melanoma cells can be enhanced due to latent
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Toxoplasma gondil infection, then this system may be found applicable





Macrophages have their origin in the bone marrow, similar to
other mononuclear cells. As monocytes, they circulate in the blood
stream for about twenty-two hours and then migrate to the tissues.
After residing in the tissues or at inflammatory sites, monocytes
mature to a more functionally active cell called the macrophage (Van
Furth and Cohn, 1968; Buhles, 1978).
Staining characteristics of macrophages help to differentiate
them from other cells, especially those cells that may be extracted
with them as peritoneal exudate cells. The cytoplasm of macrophages
appear blue with the Wright’s or Giemsa stains (Jacoby, 1967).
Positively stained macrophages appear diffuse brick red, while nega
tive cells appear yellow with the esterase dye (Tucker et al., 1977).
Macrophages appear with distinct black granules when stained with the
peroxidase dye (Cotran and Litt, 1970).
Various accessory functions have been ascribed to macrophages
in some cell-mediated immune responses. Depending on the type of
antigen, macrophages have been reported to be important as antigen
processing cells in the inductive phase of the immune response
(Gottlieb and Waldman, 1972) and as effector cells in delayed-type
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hypersensitivity, leading to target cell cytotoxicity (Alexander et
al., 1972). Evans and Alexander (1972), Krahenbuhl and Remington
(1974) and Germain et al.., (1975), have also reported that normal
macrophages obtained from unstimulated mice, may be found to be
slightly cytotoxic for tumor cells in vitro. The behaviour and
function of normal macrophages can be modified for specific tumor
cytotoxicity by their interaction with sensitized lymphocytes, or
soluble products of sensitized lymphocytes (Churchill et al., 1975;
Fidler, 1975). The term ‘~armed” macrophages was introduced by
Evans and Alexander (1970), to describe such functionally modified
macrophages. Macrophages obtained from mice immunized with either
allogeneic tumor cells (Granger and Weiser, 1964) or irradiated
syngeneic tumor cells were also reported as being “armed,” to destroy
specifically, only those tumors used in sensitizing the mice. These
investigations further reported that the presence of the antigen used
in sensitizing the mice’s lymphocytes was required for macrophage
mediated tumor cell destruction to occur. Various investigators have
also found that macrophages can be modified for non-specific tumor
cell killing and such macrophages were referred to as being “activated”
(Hibbs et al., 1972; Krahenbuhl and Remington, 1974). Although normal
macrophages may be found to be cytotoxic for tumor cells, it has been
reported that the activity of these macrophages is not as pronounced
as “armed” or “activated” macrophages (Evans and Alexander, 1972;
Germain et a].., 1975) or may even have enhancing effects on tumor
cell growth (Ghaffar et al., 1974; Martin et al., 1978).
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Rcfle of Macrophages in Tumor Suppression
ResistancetO murine tumors was first reported conferred by live
organisms of Bacillus Calinette Gu~rin (BCG), as well as methanol-
insoluble fractions of BCG (Old et al., 1959; Weiss et al., 1961).
Interest in the machanism of resistance to tumors conferred by these
and other agents was generated, because these agents were also known
to stimulate multiple resistance factors of the host. In France,
Maths et al., (1969) induced prolonged remission of acute leukemia
in children previously treated with chemotherapeutic agents~ by
employing BCG immunotherapy. Morton et al., (1970) in the United
States, used BCG immunotherapy in eight patients with melanoma,
and observed temporary regression of the tumor in five patients.
Various investigators later reported that macrophages and not
lymphocytes appeared to be the effector arm of the resistance to
tumor conferred by the different agents used (Hibbs et al., 1972;
Krahenbuhl and Remington, 1974).
The mechanism by which macrophages become activated are still
unknown. However, various investigators using in vitro systems have
reported that only cells which demonstrated abnormal growth character-•
istic in vitro were destroyed by activated macrophages (Hibbs et al.,
1972; Evans and Alexander, 1972; Evans et al., 1973; Meltzer et al.,.
1975; Piessens et al., 1975). Macrophages used by these investigators
had been activated in vivo or in vitro by one of several seemingly
unrelated mechanisms, including: infections with live BCG (Old et
al., 1959), Besnoitia jellisoni and Toxoplasma gondii (Hibbs et al.,
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1971), Cor)rnebacterium parvum (Currie and Bagshawe, 1970), Bordetella
pertusis (Novikoff, 1958; Sinkovics et al., 1970); stimulated with
Freund’s Complete adjuvant (Hibbs et al., 1972), endotoxin (Alexander
and Evans, 1971), or pyran copolymer (Kaplan et al., 1974).
How do activated macrophages discriminate between cells having
malignant, growth potentials and normal cells? The answer to this
question, it has been reported, appears to be related to certain changes
associated with the membrane of activated macrophages. These membrane
changes include increased stickiness, ruffled motility, and enhanced
glucose oxidation (Nathan et al., 1971), increased plasma membrane
adenyl cyclase activity (Remold-O’Donnell and Remold, 1974), increased
membrane glucosamine incorporation (Hammond et al., 1972), decreased
electron dense surface material (Dvorak et al.,, 1972). Tumor cells
have also been recognized to have certain membrane changes not found
in normal cells, such as electric charge (Ambrose et al., 1956),
lectin agglutinability, surface glycoprotein glycolipid and glycosy].
transferase activity (Aub et al., 1963; Burger, 1969). Piessens et
al., (1975) have suggested from these observations, that membrane
changes associated with macrophages may very likely facilitate their
interaction with tumor cells, leading to a more intimate contact ‘and
subsequent killing of the tumor cells. V
Mechanisms of Macrophage-Mediated
Tumor Cytotoxicity
Some general features of the mechanism of iuacrophage-mediated
V tumor cytotoxicity in vitro have been defined: (1) Contact between
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macrophage and the tumor cells is. a pre-requisite for killing or
inhibition to take place. Contact between a single macrophage and
tumor cell may not necessarily be permanent for tumor cell, death to
occur(Hibbs et al., 1972; Cleveland et al.,, 1974; Meltzer et al.,
1975); (2) Tumor growth inhibition is the net result of both cytostatic
and cytotoxic mechanisms and does not appear to involve phagocytosis
(Krahenbuhl and Remington, 1974). Actual death of tumor cells may
not always occur, or may contribute only a minimal role to the over
all reaction (Evans and Alexander, 1971; Keller, 1973); (3) Activated
macrophages have been demonstrated to destroy preferentially, only
abnormally growing cells, in vitro (Hibbs et al.., 1972; Meltzer et al..,
1975; Norbury and Fidler, 1975; Piessens etal., 1975; Gallily, 1975).
Enhanced glucose oxidation (Nathan et al., 1971) and generally
increased enzyme activity (Evans and Alexander, .1971), have been
reported for activated macrophages, compared to normal macrophages.
Increased lysozyme synthesis and secretion has also been reported.
associated with activated macrophages (Gordon et al., 1974). It was
also suggested by Osserman et al., (1973), that lysozyme secretion may
be the probable mediator in the anti-tumor function of macrophages.
Toxoplasma gondii
Toxoplasma gondii is an obligate intracellular protozoan parasite,
with wide geographical distribution and indiscriminate host preference,
including man (Feldman and Miller, 1956). The clinical importance of
the parasite to man was first recognized by Wolf et al., (1939), who
demonstrated that the parasite caused a fatal disease in newborn
9
infants. Fetal infection in utero by the parasite have been reported
to cause stillborn or deformed infants, chorioretinitis,. cerebral
calcification and psychomotor retardation (Sabin, 1941; Pinkerton
and Henderson, 1941).
Although congenital infection with the parasite usually produce
clinical symptoms, acquired infections have been reported to be well
tolerated by man (Feldman, 1968). Antibodies to the parasite have
been demonstrable in practically all birds and mammals (Miller and
Feldman, 1953). Experimental toxoplasmosis studies of the multipli
cation and spread of the parasite have shown that it has a predilec
tion for the cells of the reticuloendothelial system (Huidt, 1966).
The parasite can be found located in macrophages after intraperitoneal
injection (Goldman et a1.., 1958). Three morphologically different
stages in the infectious stages of the parasite have been identified.
These are the concave shaped tachyzoites, the circular shaped
bradyzoites and the oocytes usually found encysted in tissues and
feces of cats. The lethal effect of the parasite during acute
infection in man has been reported usually manifested when nematodes
encysted within tissues multiply by a process of endôdyogeny (Ludvik,
1958; Gavin et al., 1962), these destroy the membrane of cells,
causing cell death and thus tissue necrosis (Goldman et al., 1958).
The parasite has been reported to have suppressive and stimulating
effects on the immune system of its host. Experiments by Remington
et al., (1972), have shown that immunization to Toxoplasma gondii is
effected by restriction of intracellular multiplication of the
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parasite, by infected macropha.ges, as well as by a huruoral factor.
There are reports showing that latent infection with Toxoplasma gondii
enhances the suppression of such tumors as mammary carcinoma,
spontaneous leukemia, virally induced leukemia, sarcoma 180 in C3He/H,
AKR and Swiss Webster mice, syngeneic C57BL mice lymphomas and EMT-6
adenosarcomas (Hibbs et al,, 1971; Krahenbuhl and Remington, l975)~
The B16 Melanoma Tumor
In 1954, a transplantable Bl6 melanoma tumor which originated
spontaneously in C57BL mice was isolated at the Jackson laboratory,
Bar Harbor, Maine. Fidler (1970) reported that the parent line of
the tumor was passaged several times in syngeneic recipients, prior
to its establishment in tissue culture. Studies on the organ dis
tribution, arrest and survival of the B16 melanoma tumor have shown
that the tumor upon successful experimental metastasis, appears as
superficial black nodules, which grow preferentially in the lungs of
C57BL mice, after intravenous injection of single cells. -
A combination of tissue culture and animal transplantation was
used in establishing new sublines of the parent tumor (Fidler, 1972).
Melanoma tumor cells from the peritoneal cavity of mice were injected
intravenously into fresh mice, melanoma cell colonies that formed in
the lungs these mice were then surgically removed asceptically. These
colonies were then adapted to grow in a tissue culture environment,
harvested and reinjected intravenously into syngeneic recipients.
This procedure was repeated and resulted in sub-populations with
enhanced ability to colonize the lungs (Fidler, 1972). Each new
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sub-population was designated as a subline, including the Fl and FlU
sublines. Fidler’s report thus supported the suggestion made by
Nowell (1976), that tumor cell variants arise within developing tumors.
•The use of B16 Melanoma as a Model
for Tumor Metastasis
Tumor metastasis, the formation of secondary foci at sites
distant from the primary sites of introduction of a. tumor, is
influenced by a variety of factors, involving the host and certain
properties of the tumor cells. These factors contribute to the success
or failure of the metastatic process. Although the exact mechanism
of tumor metastasis is not known, five generally sequential steps have
been identified (Zeidman, 1957): (1) Invasion, wherein cells of the
primary tumor dissociate from the site of the solid tumor migrate to
tissues surrounding the primary tumor, with eventual penetration of
blood and/or lymph vessels; (2) release of tumor emboli into blood
vessels and transportation to other parts of the body; (3) the arrest
of these emboliin the capillary beds of distant organs; (4) extra
vasation, or infiltration into adjacent parenchyma. and; (5) establish
ment of a microenvironment for multiplication and finally growth into
a secondary tumor.
Melanoma cells are often highly pigmented by the black substance
melanin. In the lungs, these melanoma cells are thus characterized
by their more conspicuous appearance as black nodules, against the
lighter color background of the lungs. The appearance of these
black nodules was used by Fidler (1974), to develop a system which
allows for the quantitation of the effects of any agent on the
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metastasis of melanoma cells in vivo. Recently, in vivo suppression
of the Fl Bl6 melanoma cell sublines was demonstrated by Seele (1979).
It was found that CS7BL mice latently infected with the C56 strain
of Toxoplasma gondii, has reduced incidence of pulmonary metastasis,
following intravenous injection of the tumor cells, when compared to
critically infected or uninfected mice. In vitro studies have also
shown that B16 melanoma cells can be destroyed by inacrophages derived
from sy~geneic, allogeneic or xenogeneic mice, that had been immunized
against the tumor (Norbury and Fidler, 1975). Macrophages activated
in vitro with supernatants from lymphocytes sensitized with the B16
melanoma tumor, were also found to be cytotoxic to the Bl6 melanoma




Seven—week old, male CS7BL/6J mice were used in this study
(Cumberland Farms, Clinton, Tennessee). They were housed in the
animal facilities at the Atlanta University Center and at the Center
for Disease Control, Atlanta, Georgia.
Tumor Cells
The Fl and FlU sublines of the B16 melanoma tumor were used
as target cells in the cytotoxicity assays. These cells were obtained
from Dr. I.J. Fidler, at the Frederick Cancer Research Center,
Frederick, Maryland.
Culture Media
The Complete minimum essential medium (CMEM) used for tissue
culturing of tumor cells was that suggested. by Fidler (1975). This
consisted of minimum essential medium (MEM) supplemented with 10%
fetal calf serum, non-essential amino acids, sodium pyruvate, gluta
mine, MEM vitamin solutions and antibiotics (Penicillin-Streptomyci.n)~
The labeling medium was made up of CMEM supplemented with
tritiated thymidine (sp. act. 2 Ci/mM, New England Nuclear, Boston
Massachusetts). The concentration of tritiated thymidine in culture
medium was made up to 0.25 uCi/ml, when used in labelling tumor cells.
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The assay medium was made UP of CMEM supplemented with 2% cold
thymidine.
Propagation of Tumor Cells
In vitro, the tumor cells were grown as monolayers in either
25 cm2 or 75 cm2 tissue culture flask (Falcon Plastics, Los.
Angeles, CA) and then incubated at 37°C, 5% CO2 in humidified air.
In vivo propagation of the tumor cells was by intraperitoneal
injection of 106 viable tumor cells into CS7BL mice. Cell viability
counts were done with the trypan blue exclusion test (Boyse et al.,
.1974). Ten to fourteen days after injection, solid tumors were
extracted asceptically from the peritoneal cavity of mice. Tumor
cells thus harvested were suspended in MEM and then transferred into
tissue culture flasks containing CMEM. Sometimes, some of the sus
pended cells were used for re-injecting mice intraperitoneally.
Some of the tumor cells growing in tissue culture flasks were
sometimes harvested and stored frozen in liquid nitrogen. These
cells before being stored, were suspended in 10% dimethy]. sulfoxide
(DMSO) in MEM, and their concentration adjusted, such that each via.l
contained l0~ cells. They were stored in liquid nitrogen for
future use.
Isotope Labeling of Tumor Cells
The labeling procedure used for the tumor cells was a modifica
tion of the method of Fidler’ (1975). Tumor cells near confluence
in 25 cm2 tissue culture flasks were used. The culture medium was
aspirated and replaced with Hank’s Balanced Salt Solution (HBSS) to
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wash the cells. After washing the cells twice, they were overlaid
with the labeling medium and incubated for twenty four hours. At
the end of the labeling period, the cells were again washed with HBSS,
similar to the unlabeled cells. A rubber policeman was used to
detach the labeled cells from the bottom of the tissue culture flask.
Detached cells were then washed twice by centrifugation, with HBSS and
then suspended in assay medium, for use in cytotoxicity assays.
Establishment of Latent Infection
with Toxoplasma gondii
Latent infection was established for Toxoplasn~a gond.ii in C57BL
mice, using the procedure developed by Ruskin and Remington (1968).
Mice were injected with lO~ parasites of the C56 strain. Three days
after infection, the mice were given sulfadiazine treatment, by
adding 500 mg of sulfadiazine and 46 mg of sodium bicarbonate to a
liter of their drinking water. Three weeks later, they were taken
off the sulfadiazine treatment. Such mice were used about two weeks
later to extract peritoneal macrophages.
Macrophages
Macrophages were obtained from the peritoneum of either normal
or latently infectedC57BL mice, using the procedure described by
Meltzer et al., (1975). Four to five days prior to extraction of
macrophages, mice were injected intraperitoneally with 2 ml of 10%
peptone. To extract peritoneal macrophages, mice were decapitated,
in order to prevent contaminating the peritoiieal exudate cells with
blood cells. The skin covering the peritoneum was retracted without
exposing the peritoneal cavity itself. In order to maintain asepsis,
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the exposed area was flooded with 70% alcohol, before inserting
the needle in this area. Two mililiters of HBSS were then injected
into the peritoneum of the mouse. Almost immediately after each
injection, the peritoneal exudate fluid was aspirated carefully
back into the syringe. Peritoneal exudate cells thus harvested
were then washed with fresh HBSS by centrifugation, and then
suspended in MEM. The cell concentration of the macrophages was
then adjusted to ~ cells/mi, for incubation in 25 cm2 tissue
culture flasks containing MEM supplemented with 20% fetal calf serum
and antibiotics (Penicillin-Streptomycin). One hour after incubation,
non-adherent cells were washed off with HBSS by aspiration and all
remaining adherent cells were detached with a rubber policeman. The
detached cells were then washed twice with fresh HBSS, by centrifuga-~
tion. Washed cells were then adjusted to concentration of 2 x l0~
cells/ml and 2 x 106 cells/mi, for seeding into appropriate assay
wells.
Cytotoxicity Assay
Cytotoxicity assays were performed using a modification of the
method of Norbury and Fidler (1975). Pre-labeled tumor cells were
seeded at concentrations of 2 x ~ cells/mi assay medium, into multi-
dish disposotray assay wells (Limbro ChemicaiCo., New Haven,
Connecticut), or into microtiter plate wells (Falcon Plastics, Los
Angeles, CA). The seeded cells were then incubated for twelve hours
at 37°C, 5% CO2 in humidified air. Prior to adding macrophages, wells
with pre-labeled cells were washed twice with HBSS to remove any
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non-adherent cells that were present in the wells. Macrophages
were then added to appropriate wells, such that cells would inter
act at ratios of either 10:1 or 100:1 macrophage/tumor cells.
Control wells received no macrophages, but only 1 ml of assay
medium. All cells were then incubated for either twenty~four or
seventy-two hours, at 37°C, 5% CO2 in humidified air. At the end
of each twenty-four hour assays, supernatants were aspirated from
each assay well, and placed into separate scintillation counter
vials containing 10 ml of Aquasol-2 (New England Nuclear, Boston,
• Massachusetts). All remaining adherent cells were lysed with 2%
sodium dodecyl sulfate (SDS) and were also put into separate scintilla
tion counter vials containing 10 ml of Aquasol-2. All specimen were
• then counted in the Beckman LS 230 Liquid scintillation counter. In
the seventy—two hour assays, supernatants in assay wells were aspirated
and monitored for radioactivity in Aquasol—2, at twenty-four hour
inter~1s. After each aspiration, cells remaining in the assay wells
were re-fed with fresh assay medium. Adherent cells remaining at the
ei~d of the seventy-two hour assay period were then lysed with 2% SDS
and also monitored for radioactivity, similar to the procedure of the
twenty-four hour assays.
Materials for Lysozyme Assay
The standard lysozyme used in this study was a commercially
purified egg white lysozyme extract (Batch #7017, Miles Laboratory,
Elkhart, Indiana). Its specific activity was 12,500 units per milli
gram protein. One unit of activity was described as the amount of
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enzyme that would cause a decrease of 0.001 optical density units per
minute, in a suspension of Micrococcus lysod.eikticus.
Macrophage lysozyme samples were obtained from ~ macrophages
suspended in 0.067 M phosphate buffer, pH 7.0, using the procedure
described by Gordon et al., (1974). The macrophages were subjected
to five cycles of freezing and thawing in order to lyse the cells
and release their lysozyme into the supernate. The suspension
containing lysed cells were then centrifuged at 1,000 x g for ten
minutes. The cell free supernatants (extract) were then used for
assaying macrophages lysozyme.
Micrococcus luteus suspended in 0.067 M phosphate buffer, pH
7.0 was used as substrate for assaying lysozyme activity in this
study. The organism was obtained from Thomas Price. at the Georgia
State University, Biology Department, Atlanta, Georgia.
Lysozyme Assay
The method used in assaying lysozyme activity was similar to that
described by Gordon et al., (1974). The density of Micrococcus luteus
in suspension was adjusted to read 0.400 on the abosrbance scale at
450nM using either the Hitachi 102 or Zeiss PM QIT spectrophotometer.
A standard curve was prepared for each macroph~ge~~lYs~zyme assay
performed, using the standard lysozyme concentrations c~f 0.1 ug/ml to
2.0 ug/ml. When using the Hitachi spectrophotometer, 0~l1 ml of
standard lysozyme samples. were added to 1 ml of appropr~ate bacterial
suspensions; while 0.05 ml of standard lysozyme samples)~ere added to
0.5 ml of appropriate bacterial suspensions, when using the Zeiss
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spectrophotometer. The changes in the absorbance caused by different
lysozyme concentrations when added to separate bacterial suspensions
were then recorded at five second intervals forninety seconds. The
velocity of decrease in absorbance per minute caused by the different
standard lysozyme concentrations was then computed. The standard
curves of velocity versus standard lysozyme concentrations were then
used in estimating the amount of lysozyme activity detected in the
different macrophage extracts assayed.
Macrophage lysozyme content was assayed by establishing a
two—fold dilution series in six tubes from each macrophage extract.
These were then used for lysozyme assays, similar to the procedure
stated for the standard lysozyme concentrations.
Statistical Analysis
This was carried out by Student’s-t test (Wayne, 1978). For
the cytotoxicity assay data, statistical analysis was used to deter-
mine the significance of the difference between the percent tritiated
thymidine released spontaneously by tumor cells (controls), compared
to the percent tritiated thymidine released from tumor cells incubated
with macrophages (experimentals).
For the lysozyme assay data, the significance of the difference
between the units of lysozyme activity detected~ in normal macrophage
extracts (controls) was compared to the activity detected in the
extracts of macrophages obtained from mice with latent Toxoplasma
gondii infection (experimentals).
20







2 1) S1 + (n2 - l)S2Sp= 2
U1 + fl2 -
Sp is the pooled estimate; n1 is the number of control .data;.~n2 is the
number of experimental data; X1 is the mean of the control data;
is the mean of experimental data; S1 is the standard deviation of
the mean of the control data; S2 is the standard deviation of the




Rate of Tritiated Thymidine Uptake
by Tumor Cells
Since the release of tritiated thyinidine from pre-labeled tumor
cells was to be used as the index of cytotoxicity, it was thought
necessary to determine the rate at which the Fl and FlO melanoma cells
would incorporate the tritiated thymidine supplied them, as well as
the rate at which the labels incorporated might be lost spontaneously.
Table 1 shows the results of the rate of tritiated thymidine in—
corporation by tumor cells within twenty four hours. It is seen that
50% of the labels supplied was incorporated by the FlO melanoma cells,
while Fl cells incorporated 40% of the labels supplied. Although
there is a slight difference in the rate of tritiated thymidine in
corporation by both cell sublines, this may be due to variations in
the number of cells seeded into assay wells rather than due to any
metabolic differences between the cell sublines in vitro.
Rate of Spontaneous Release of Tritiated
Thymidine from Tumor Cells
The rate of spontaneous release of tritiateci thymidine in
corporated by the tumor cells is shown in Table 2. It is seen that
during the twenty_four hour period, both the Fl and PlO melanoma
cells released over 30% of the tritiated thymidine they had
V 21
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Table 1. Tritiated Thymidine Uptake by B16 Melanoma
Cells
Cell linea ~p~1b Medium CPM Adherent cellsC % Uptaked
Fl cells 13,583 + 476 40%
33,969 + 414
FlO cells 17,004 ÷ 707 50%
a1 x 106 cells were seeded into disposotray assay wells and then
incubated for 24 hrs with 1 ml of labeling medium.
bcounts per minute.
CAdherent cells were lysed with 1 ml of sodium dodecyl sulfate (SDS)
and then monitored for radioactivity.
d ~ u take CPM adherent cells ~ 100
CPM labeling medium
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Table 2. Spontaneous Release of Tritiated Thymidine from B16
Melanoma Cells
CPM CPM % Spontaneous
Cell line Supernatant Adherent ceiisb Total CPMC release
Fl cells 4,785 + 42 9,269 + 56 14,054 + 72 34%
FlO cells 4,854 -‘- 31 9,878 + 70 14,729 + 150 33%
a1 x 106 pre—labeled cells wereseeded into disposotray assay
wells and incubated with 1 ml of assay medium for 24 hrs.
bAdherent cells were lysed with 1 ml of 2% SDS after aspirating
the supernatants in the assay wells.
~ of CPM obtained in the supernatants and adherent cells.
d CPM Supernatant




Rate of Tritiated Thymidine
Uptake by Macrophages V
Macrophages do not divide, or do so very poorly in vitro.
However, it was not known whether the macrophages used in this study
would incorporate tritiated thymidine when they are incubated in the
labeling medium for twenty-four hours. It was also thought necessary
to determine whether the macrophages would incorporate tritiated
thymidine as a response to contact with tumor cells. By incubating
~ macrophages in labeling medium with or without killed tumor cells
for twenty-four hours, the rate of tritiated thymidine incorporation
by the macrophages was determined, similar to the procedure used for
the tumor cells. As would be expected when there is lack of active
cell division, it is apparent from the results shown in Table 3, that
the macrophages failed to actively incorporate tritiated thymidine in
vitro. .
Cytotoxicity Assays
The results of twenty-four hour cytotoxicity assays, using either
the Fl or FlO melanoma cells as target cells, and macrophages
obtained from either uninfected or latently infected mice as
effector cells., are shown in Table 4 and Table 5. Over 30% of the
total tritiated thymidine incorporated by the tumor cells were
detected spontaneously released. When tumor cells were incubated
with macrophages, the percent tritiated thymidine released by these
tumor cells were found to be higher than for tumor cells incubated
alone. With the ninety-five percent confidence used in analyzing
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Table 3. Tritiated Thymidine Uptake by Macrophages
MacrophageSa
Normal Activated
Alone + Killed cell? Alone + Killed cells
CPM Supernatant 87,413 + 516 82,624 + 1,283 92,624 + 327 80,717+982
CPM Adherent
cells 560 + 282 422 + 58 409 + 64 501 + 125
% Uptake 0.46% 0.5% 0.4% 0.6%
a2 x lO~ macrophages were seeded into disposotray assay wells
and incubated with or without killed melanoma cells in 1 ml
of labeling medium for 24 hrs.
x 106 melanoma cells were frozen and thawed twice, in order
to kill the cells, before adding to appropriate assay wells.
L_iL I ~IIF±II[
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Table 4. In vitro Macrophage—mediated Cytotoxicity for Fl
Melanoma Cells
Cell CPM CPM d
Ceilsa ratio supernatantsb Adherent cellsC Release
Fl cells 1,193 +138 2,143 + 381 35%*
Normal macro.e
+
Fl cells 10:1 2,075 + 584 1,519 + 210
Activated macro.
+
Fl cells 1,711 + 392 1,380 + 230
Normal Macro.
+
Fl cells 2,463 + 273 1,132 + 69 68%**
Activated macro. 100:1
+
Fl cells 1,759 + 615 1,529 + 580
a105 pre-labeled tumor cells were seeded into assay wells and
normal or activated macrophages added into appropriate wells.
bsupernatants in each assay well were aspirated and monitored
for radioactivity.
CAll remaining adherent cells were lysed with 2% SDS and also
monitored for radioactivity.








Table 5. In vitro Macrophage-mediated Cytotoxicity for FlO
Melanoma Cells
Cell CPM CPM
Cellsa ratio supernatantsb Adherent cellsC Released
FlO cells 1,824 + 287 3,334 + 1,000 36%*
Normal macro.e
.7-
FlU cells 10:1 4,285 ÷ 820 2,748 + 440 60%~~
Activated macro.
+
FlU cells 3,236 + 599 2,325 + 539
Normal macro.
+
::F10 cells 3,496 + 305 2,922 + 146
Activated macro. 100:1
+
FlO cells 2,364 ÷ 288 2,574 + 049 50%**
a10s pre—labeled tumor cells were seeded into assay wells
and normal or activated macrophages were added into appropriate
wells.
bsupernatai~ts in each assay well were aspirated at the end of
24 hrs, and monitored for radioactivity.
CAdherent cells were lysed with SDS and also monitored for
radioactivity.







these data; the increased percent release of tritiated thymidine in
the presence of macrophages was determined to be significant. There
was no significant different in the percent tritiated thymidine
released by the tumor cells incubated with normal macrophages compared
to cells incubated with macrophages obtained from latently infected
mice. There was also no significant difference in the percent
tritiated thymidine released by tumor cells at the two incubation
ratios of 10:1 and 100:1 macrophage/tumor cell used.
In Table 6 and Table 7 are seen the results of cytotoxicity
assays conducted over seventy-two hour assay periods using the Fl
and FlO melanoma cells as target cells, respectively. In both
assays, it was found that the percent tritiated thymidine released
by the tumor cells incubated with macrophages was most dramatic at
culture hours twenty-four and seventy-two, as determined by radio
activity in supernatants at these hours. At the end of the assay,
a comparison of the total percent of tritiated thymidine released
by tumor cells incubated alone compared to tumor cells incubated
with macrophages. showed there was significant increase in the
tritiated thymidine released in the presence of the macrophages.
No significant difference was determined in the percent tritiated
thymidine released by tumor cells incubated with either normal
macrophages or macrophages obtained from latently infected mice.
There was no significant increase in the total percent tritiated
thymidine released by tumor cells, when the concentration of
macrophages interacting with them was increased. It was thought
Table 6. In vitro Macrophage-mediated Cytotoxicity for Fl Melanoma Cells
. Supernatantsa
Cell % % % CPM adherent % Total
Macrophagesb ratio 24 hr ReleaseC 48 hr Released 72 hr Releasee cells Release
None 3,619 21 ÷ 2% 1,312 9 ÷ 2% 1,986 15 + 2% 9,933 40 + 2%*
Normal 5,326 32 + 5% 1,580 14 + 3% 2,115 22 + 3% 7,285 55 + 2%~
10:1 — — —
Activated 5,052 31 + 3% 1,546 13 + 2% 2,020 18 + 3% 7,560 53 + 3%**
Normal 5,766 35 ÷ 5% 1,652 12 + 4% 1,754 19 + 3% 7,164 56 + l%**
Activated 100:1 4,791 29 + 4% 1,536 13 ÷ 3% 2,358 23 + 4% 7,684 53 .~. 3%**
aSupernatants were aspirated from each assay well at 24 hour-intervals and monitored for
radioactivity. Cells remaining in each well were then re-fed with fresh assay medium after
each aspiration.
b2 x l0~ pre-labeled tumor cells were seeded into all assay wells. Normal or activated
macrophages were then added into appropriate assay wells.
c CPM supernatant at 24 hrs~ Release = Total CPM recovered x 100
d CPM supernatant at 48 hrs~ Release = — x 100
Total CPM recovered - CPM supernatant at 48 hrs
e CPM supernatant at 27 hrs
~ Release = X 10.0
Total CPM recovered - CPM recovered in 48 hrs
% Release = CPM total label released in 72 hrs x 100Total CPM recovered
* Control
**p < 0.05
Table 7. In vitro Macrophage-mediated Cytotoxicity for FlO Melanoma Cells
Sl~pernatantsa
Cell % d % CPM adherent % Tota
Macrophagesb ratio 24 hr Releasec 48 hr Release 72 hr Releasee cells Release
None 2,703 19 ÷ 2% 3,500 32 + 2% 2,451 31 + 2% 5,443 61 + 2%*
Normal 4,807 33 + 2% 3,462 37 ÷ 1% 3,022 51 + 5% 2,884 79 +
10:1
Activated 4,272 29 + 2% 3,202 31 + 3% 3,383 50 + 9% 3,374 76 + 6%**
Normal 100:1 3,765 26 + 3% 3,053 29 + 5% 3,108 43 + 4% 4,067 70 ÷ 3%~*
Activated 4,144 29 ÷ ?% 2,779 26 + 5% 3,963 54 + 7% 3,370 76 +
aSupernatants were aspirated from each assay well at 24 hour-intervals and monitored for
radioactivity. Cells remaining in each assay well were re-fed with fresh assay medium
after each aspiration.
b2 x ~ pre-labeled tumor cells were seeded into all assay wells. Normal or activated
macrophages were then added into appropriate assay wells.
c ~ Release — CPM supernatant at 24 hrs x 100
Total CPM recovered
d % Release CPM supernatant at 48 hrs x 100
Total CPM recovered - CPM supernat.ant at 48 hrs
e % Release CPM supernatant at 72 hrs ~ 100
Total CPM recovered - CPM recovered in 48 hrs




** p < 0.05
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necessary to determine the degree of activation of the macrophages
obtained from both latently infected or uninfected mice, since both
types of macrophages appeared to be equally cytotoxic for the tumor
cells during the twenty-four hour cytotoxicity assays previously
conducted.
Lysozyme Assay
Since increased lysozyme activity has been reported associated
with macrophage activation, this enzyme was used in estimating
macrophage activation in this study. Table 8 shows the amount
of lysozyme activity detected in macrophage extracts obtained from
~ cells. Using the standard curve, about 0.900 units of lysozyme
activity was detected in the normal macrophage extracts assayed,
while about 1.170 units of lysozyme activity was detected in the
extracts of macrophages obtained from latently infected mice. These
results showed significantly higher lysozyme activity in the extracts
of macrophages obtained from latently infected mice, compared to the
extracts of macrophages obtained from uninfected mice.
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O.D. unitsa/min/mi extract .011 -I- .007* .022 + 005~
Units lysozyme activityb/mi extract .900 + .110 1.170 + .150
aOD. means optical density, also referred to as absorbance.
bStandard curve was prepared using commerical egg white
lysozyme extract to estimate the units of lysozyme activity







The results of the cytotoxicity assays in this study shows that
both the macrophages obtained from mice with latent Toxoplasma gondii.
infection and uninfected mice were equally cytotoxic for the Fl and
FlO B16 melanoma cells in vitro. These results also showed that
increasing the number of macrophages interacting with the tumor cells
in vitro did not cause any significant increase in the cytotoxicity
detected either during the twenty-four hour or seventy-two hour
assays.
These results were not totally consistent with the result of
the in vitro macrophage-mediated cytotoxicity reported for B16 melanoma
cells by Norbury and Fidler, (1975). Norbury and Fidler in their
study, used macrophages that had been activated in vivo by immunizing
mice to the B16 melanoma tumor. In vitro macrophage-mediated
cytotoxicity was estimated about seventy percent as determined by
radioactivity in the supernatants monitored over a five-day period
at the macrophage/tumor cell ratio of ten to one. At the higher
macrophage/tumor cell concentration of a hundred to one, macrophage—
mediated cytotoxicity was detected to have increased to about ninety
percent. Although normal macrophages, when incubated with tumor cells
at the ratio of ten to one, did not exhibit any cytotoxic effect on
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the tumor cells, about twenty percent cytotoxicity was detected at
the normal macrophage/tumor cell ratio of a hundred to one. Krahenbuhl
and Remington (1975), studying the cytostatic effects of Toxoplasma
gondii activated macrophages on L-cells, found that the activated
macrophages caused significant inhibition of about forty percent
in the uptake of tritiated thymidine by L-cells incubated with
activated macrophages at the ratio of ten to one .macrophages/tumor
cells within forty eight hours. Over ninety percent inhibition was
observed when activated macrophages were incubated with L-cells at a
ratio of a hundred to one for forty eight hours. However, normal
macrophages failed to cause any significant inhibition in the uptake
of tritiated thymidine by the L—cells.
The fact that increasing the macrophage concentration did not
cause any significant increase in the cytotoxicity of the macrophages
on the Fl and FlO melanoma cells in this study. suggested that some
other factor not determined in this study may have been responsible
for the cytotoxicity detected for the macrophages.
The fact that the normal macrophages and macrophages obtained
from mice with latent Toxoplasma gondii infection were equally
cytotoxic for the Fl and FlO melanoma cells in this study suggested
that the normal macrophages may have also become non-specifically
activated for tumor killing. Certain molecules used in eliciting
macrophages in mice, such as thioglycollate (Argyris, 1967) and peptone
(Calderone et al., 1975) have been implicated in non-specific activa
tion of normal macrophages. The cytotoxic capabilities reported for
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such macrophages were, however, less than were reported for activated
macrophages obtained from latently infecte4 mice. The use of peptone
in eliciting macrophages in this study may have activated the normal
macrophages for the non—specific cytotoxicity detected on the
melanoma cells. Evans and Alexander. (1972), Germain et al., (1975)
and Meltzer etal., (1975) have also reported that normal macrophages
may be found to be slightly cytotoxic for tumor cells, but less
cytotoxic than activated macrophages.
The similarities in the cytotoxicity detected for both types
of macrophages used in this study necessitated estimating their
degree of activation by lysozyme content. The results of the lysozyme
assay showed greater lysozyme activity in the extracts of macrophages
obtained from latently infected mice than in normal macrophage
extracts. This was consistent with the observations reported in.the•
study of Gordon et al., (1974). Increased lysozyme secretion was
detected associated with activated macrophages by these investigators.
Greater lysozyme activity thus suggested that the inacrophages obtained
from mice with latent Toxoplasma gondii infection, used in this study,
were indeed more activated than the macrophages obtained from unin
fected mice.
The mechanism by which macrophages become activated is still not
totally known; neither is the mechanism by which activated macrophages
kill tumor cells nor how tumor cell lysis is triggered. A standard
method for quantitating macrophage activation ~ se has, therefore,
not yet been established. Various investigators have thus reported
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using various procedures to estimate relative macrophage activation
including: morphological changes (Mackaness, 1970); determination of
phagocytosiS (Fowles et al., 1973); glucose oxidation assays (Nathan
et al., 1973) and lysozyme assays (Gordon et al., 1974). Nathan et
al., (1973) further noted, however, that changes associated with
macrophage activation does not necessarily imply that the functional
alterations are necessarily equivalent to those accompanying the
activation of macrophages in vivo.
The results of the cytotoxicity assays in this study were also
not totally consistent with the results. of the in vivo suppression of
the B16 melanoma cell metastasis reported by Seele (1979). In her
study it was found that latent Toxoplasma gondii infection in CS7BL
mice affected about eighty to ninety percent suppression of the
incidence of B16 melanoma cell metastasis. compared to the incidence
in üninfected mice. It would thus be expected from the results of
the in vivo study that macrophages obtained from mice with latent
Toxoplasma gondii infection would be more cytotoxic for the Bl6
melanoma cells, in vitro than the normal macrophages. It is known
that the conditions under which activated macrophages and tumor cells
interact in vitro, are not the exact biologic conditions in which
such cells would be found interacting in vivo. Due to the artificial
nature of the in vitro system, some critical biologic factors required
for the immunologic suppression of the B16 melanoma cells in vivo, may
be lacking in the in vitro system. It has been reported that
macrophage-mediated tumor killing in an in vivo or in vitro .
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environment may be affected by chemical signals originating within
the two different environments. These signals include: (1) host
factors that influence activated macrophage tumor killing potentials
in vivo, before they are harvested from mice with chronic infection;
(2) serum factors that further moderate activated macrophage tumor
killing potentials in vitro (Hibbs et al., 1977). Latent ~2lasrna
gondli infections have, for instance, been reported to provide a
continuing stimulus for the production of activated iuacrophages in
mice (Hibbs et al., 1971), It has been reported that. incubating
normal or activated macrophages in supernatants from cultures of
sensitized lymphocytes or syngeneic spleen cells may render normal.
macrophages activated, while activated macrophages are able to
retain their activated state longer (Evans and Alexander, 1972;
Meltzer et al., 1975; Churchill et al., 1975). It is speculated.
from the results of this study, that further incubating the macro~
phagesw:i.th supernatants from cultures of appropriately sensitized
lymphocytes or spleen cells may provide the biologic environment
to enharLc~e the cytotoxicity of Toxoplasma gondil-activated macrophages
for the 516 melanoma cells in vitro. Such sensitized lymphocytes
or spleen cells may probably be obtainable from mice with latent
Toxo~asma gondii irkfection,
The results of this study thus show that although mac.rophages
obtained from mice with latent Toxqp1asmagond~~ infection appear
to he more activated than the macrophages obtained from uninfected
mice, both types of ma.crophages were oqualiy cytotoxic for the F]
I - — -.
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and FlO Bl6 melanoma cells, in vitro. Since Toxoplasma gondii has
been reported to be capable of affecting the suppression of B16
melanoma eel]. metastasis in vivo (Seele, 1979) and evidence of
macrophage-mediated cytotoxicity has been shown in this study,
inacrophages obtained from mice with latent Toxoplasma gondii infection
are potentially cytotoxic for the B16 melanoma cell sublines used in
this study, in vitro. it is, therefore, concluded that this type of
macrophage-mediated cytotoxicity may be found helpful in further
determining the mechanism of non-specific suppression of tumor
metastasis, as well as in developing immunotherapeutic methods that




1. Cytotoxicity assays, designed to determine macrophage-mediated
cytotoxicity for the Fl and FlO sublines of the B16 melanoma
tumor in vitro, as well as lysozyme essays, used in estimating
the degree of macrophage activation, were performed in this
study.
2. Macrophages obtained from mice with the latent Toxoplasma gondii
infection and uninfected mice were equally cytotoxic for the Fl
and FlO B16 melanoma cells in vitro, as seen by the increased
radioactivity in the supernatants of cultures of pre-labeled
tumor cells incubated with macrophages, when compared to tumor
cells~ incubated, alone.
3. Macrophages obtained froni mice with latent Toxoplasma gondii
infection appeared to be more activated than the macrophages
obtained from uninfected mice by lysozyrne content.
4. The potential for cytotoxicity on the Fl and FlO Bl6 melanoma
cells demonstrated by the macrophages, although not enhanced due
to latent Toxoplasma gondii infection under the assay conditions
used in this study, suggests that this system could be further
modified for studying the mechanism of non-specific suppression
of the incidence of tumor metastasis.
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